Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XH-30
- Development stage
- Preclinical
- Lead developer
- China Pharmaceutical University
01
Overview
XH-30: sourced facts only. name: "Among these compounds, XH-30 exhibited significant PKMYT1 inhibitory activity (IC50 = 4.1 nM) and induced G2/M phase release in MDA-MB-231 cells (a P53-mutated TNBC cell line), demonstrating promising antitumor effects in vivo (TGI = 58%)." [PMID:41427887]; target: "Among these compounds, XH-30 exhibited significant PKMYT1 inhibitory activity (IC50 = 4.1 nM) and induced G2/M phase release in MDA-MB-231 cells (a P53-mutated TNBC cell line), demonstrating promising antitumor effects in vivo (TGI = 58%)." [PMID:41427887]; developer: "Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China." [PMID:41427887]; stage: "Among these compounds, XH-30 exhibited significant PKMYT1 inhibitory activity (IC50 = 4.1 nM) and induced G2/M phase release in MDA-MB-231 cells (a P53-mutated TNBC cell line), demonstrating promising antitumor effects in vivo (TGI = 58%)." [PMID:41427887]
02
Targets
PKMYT1 (Protein kinase membrane associated tyrosine/threonine 1)
Beyond the preview
Go deeper on XH-30.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XH-30.